What is the price target for WST stock?
23 analysts have analysed WST and the average price target is 352.97 USD. This implies a price increase of 19.51% is expected in the next year compared to the current price of 295.36.
NYSE:WST • US9553061055
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for WEST PHARMACEUTICAL SERVICES (WST).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-27 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-04-14 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-13 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-03 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-02 | Morgan Stanley | Initiate | Equal-Weight |
| 2025-10-29 | TD Cowen | Initiate | Buy |
| 2025-10-27 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-24 | UBS | Maintains | Buy -> Buy |
| 2025-10-24 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-15 | Rothschild & Co | Initiate | Buy |
| 2025-07-25 | UBS | Maintains | Buy -> Buy |
| 2025-07-25 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-06-24 | Barclays | Initiate | Equal-Weight |
| 2025-03-18 | Evercore ISI Group | Initiate | Outperform |
| 2025-02-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-01-08 | Citigroup | Initiate | Buy |
| 2024-12-13 | Wolfe Research | Initiate | Peer Perform |
| 2024-12-13 | B of A Securities | Maintains | Buy -> Buy |
| 2024-12-12 | UBS | Upgrade | Neutral -> Buy |
| 2024-02-16 | UBS | Maintains | Neutral -> Neutral |
| 2024-02-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-07 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-27 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.95B 2.18% | 2.893B -1.92% | 3.074B 6.25% | 3.282B 6.76% | 3.486B 6.22% | 3.735B 7.14% | 4.127B 10.50% | 4.538B 9.96% | |
| EBITDA YoY % growth | 842.4M -3.78% | 744.9M -11.57% | 802.4M 7.72% | 883.86M 10.15% | 962.97M 8.95% | 1.071B 11.22% | 1.2B 12.04% | 1.308B 9.00% | |
| EBIT YoY % growth | 705.1M -6.60% | 589.5M -16.39% | 631M 7.04% | 701.24M 11.13% | 777.01M 10.81% | 866.79M 11.55% | 972.13M 12.15% | 1.063B 9.35% | |
| Operating Margin | 23.90% | 20.38% | 20.53% | 21.37% | 22.29% | 23.21% | 23.56% | 23.42% | |
| EPS YoY % growth | 8.08 -5.72% | 6.75 -16.46% | 7.29 8.00% | 8.11 11.24% | 8.99 10.83% | 10.11 12.48% | 11.06 9.45% | 11.22 1.41% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.11 14.71% | 2.12 8.40% | 2.24 10.02% | 1.91 -10.30% | 2.24 5.91% | 2.39 12.27% | 2.41 7.47% | 2.06 7.84% | 2.44 9.34% | 2.63 10.09% | 2.74 13.47% |
| Revenue Q2Q % growth | 847.96M 10.63% | 826.02M 2.66% | 837.06M 3.98% | 824.79M -2.38% | 871.15M 2.73% | 883.66M 6.98% | 889.75M 6.29% | 854.5M 3.60% | 913.74M 4.89% | 950.59M 7.57% | 960.99M 8.01% |
| EBITDA Q2Q % growth | 228.02M -4.67% | 230.23M -22.61% | 239.18M -30.71% | 208.39M -7.26% | 235.41M 3.24% | 249.24M 8.26% | 253.16M 5.84% | 221.88M 6.47% | 255.55M 8.56% | 273.01M 9.54% | 284.49M 12.38% |
| EBIT Q2Q % growth | 180.06M 14.11% | 185.49M 7.16% | 195.84M 12.68% | 165.87M -7.59% | 192.18M 6.73% | 205.94M 11.02% | 209.6M 7.03% | 174.41M 5.15% | 208.7M 8.60% | 223.5M 8.53% | 234.43M 11.85% |
All data in USD
23 analysts have analysed WST and the average price target is 352.97 USD. This implies a price increase of 19.51% is expected in the next year compared to the current price of 295.36.
WEST PHARMACEUTICAL SERVICES (WST) will report earnings on 2026-07-22, before the market open.
The consensus EPS estimate for the next earnings of WEST PHARMACEUTICAL SERVICES (WST) is 2.11 USD and the consensus revenue estimate is 847.96M USD.
The expected long term growth rate for WEST PHARMACEUTICAL SERVICES (WST) is 6.47%.